Precipio, Inc. (PRPO)
NASDAQ: PRPO · Real-Time Price · USD
5.27
-0.18 (-3.30%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States.
It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels.
It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.
Precipio, Inc.
Country | United States |
Industry | Diagnostics & Research |
Sector | Healthcare |
Employees | 57 |
CEO | Ilan Danieli |
Contact Details
Address: 4 Science Park, 3rd Floor New Haven, Connecticut 06511 United States | |
Phone | 203 787 7888 |
Website | precipiodx.com |
Stock Details
Ticker Symbol | PRPO |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001043961 |
CUSIP Number | 74019L503 |
ISIN Number | US74019L6020 |
Employer ID | 91-1789357 |
SIC Code | 3826 |
Key Executives
Name | Position |
---|---|
Ilan Danieli | Founder, President, Chief Executive Officer and Director |
Ahmed Zaki Sabet | Chief Operating Officer |
Dr. Ayman A. Mohamed M.D. | Chief Technology Officer |
Matthew Gage | Chief Financial Officer |
Miri Chiko-Radomski | Chief Legal Counsel and People Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 11, 2024 | 144 | Filing |
Nov 12, 2024 | 144 | Filing |
Nov 7, 2024 | 8-K | Current Report |
Nov 6, 2024 | 10-Q | Quarterly Report |
Sep 6, 2024 | 8-K | Current Report |
Aug 15, 2024 | 8-K | Current Report |
Aug 13, 2024 | 10-Q | Quarterly Report |
Aug 2, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Jun 25, 2024 | 8-K | Current Report |
Jun 13, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |